

AZD-1222

S

Urticarial vasculitis: case report

A 78-year-old man developed urticarial vasculitis following vaccination with AZD-1222 against COVID-19.

The man received first dose of AZD-1222 [Oxford–AstraZeneca COVID-19 vaccine; *route and dosage not stated*]. However, one day after receiving AZD-1222, he experienced sore throat and a mild urticarial rash. Shortly, he experienced spontaneous regression. After 1 week, he experienced wheals and a diffuse livedoid skin rash which were limited to the arms and legs. Therefore, he again presented to the clinic. A 4mm punch biopsy showed a pattern of superficial perivascular and interstitial dermatitis. In addition, neutrophils and leukocytoclasia with the formation of nuclear dust in association with extravasated erythrocytes among the collagen bundles were observed at high power. There were extremely dilated blood vessels in the papillary and mid dermis. Blood tests showed normal C3, C4 and platelet level. His renal function was also normal. Antinuclear antibody, anti-DNA and FR [sic] revealed negative result. Based on investigational findings, he was diagnosed with urticarial vasculitis.

The man was treated with methylprednisolone. After 10 days of treatment, an initial improvement was observed. At 2 weeks after the end of methylprednisolone taper, complete resolution of the clinical manifestations was observed. The development of urticarial vasculitis was attributed to AZD-1222.

Baraldi C, et al. Unique Case of Urticarial Skin Eruptions After COVID-19 Vaccination. *American Journal of Dermatopathology* 44: 198-200, No. 3, Mar 2022. Available from: URL: <http://doi.org/10.1097/DAD.0000000000002036>

803648597